PL3710586T3 - Kwasy nukleinowe do hamowania ekspresji LPA w komórce - Google Patents

Kwasy nukleinowe do hamowania ekspresji LPA w komórce

Info

Publication number
PL3710586T3
PL3710586T3 PL18803644.6T PL18803644T PL3710586T3 PL 3710586 T3 PL3710586 T3 PL 3710586T3 PL 18803644 T PL18803644 T PL 18803644T PL 3710586 T3 PL3710586 T3 PL 3710586T3
Authority
PL
Poland
Prior art keywords
lpa
cell
nucleic acids
inhibiting expression
inhibiting
Prior art date
Application number
PL18803644.6T
Other languages
English (en)
Inventor
Sibylle DAMES
Steffen Schubert
Stephan TENBAUM
Christian Frauendorf
Lucas Bethge
Judith HAUPTMANN
Adrien WEINGÄRTNER
David Anthony RIDER
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17201449.0A external-priority patent/EP3483270A1/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of PL3710586T3 publication Critical patent/PL3710586T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18803644.6T 2017-11-13 2018-11-13 Kwasy nukleinowe do hamowania ekspresji LPA w komórce PL3710586T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17201449.0A EP3483270A1 (en) 2017-11-13 2017-11-13 Products and compositions
EP18179175.7A EP3483271A3 (en) 2017-11-13 2018-06-21 Products and compositions
GB201815915 2018-09-28
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
PL3710586T3 true PL3710586T3 (pl) 2023-03-20

Family

ID=66439085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18803644.6T PL3710586T3 (pl) 2017-11-13 2018-11-13 Kwasy nukleinowe do hamowania ekspresji LPA w komórce

Country Status (22)

Country Link
US (3) US11319537B2 (pl)
EP (2) EP3710586B1 (pl)
JP (1) JP7245254B2 (pl)
KR (1) KR102553382B1 (pl)
CN (2) CN111465694A (pl)
AU (1) AU2018363840B2 (pl)
BR (1) BR112020009152A2 (pl)
CA (1) CA3081905C (pl)
DK (1) DK3710586T3 (pl)
ES (1) ES2938193T3 (pl)
FI (1) FI3710586T3 (pl)
HR (1) HRP20230127T1 (pl)
HU (1) HUE061265T2 (pl)
IL (1) IL274503B2 (pl)
LT (1) LT3710586T (pl)
MX (1) MX2020004897A (pl)
PL (1) PL3710586T3 (pl)
RS (1) RS63955B1 (pl)
SG (1) SG11202003230UA (pl)
SI (1) SI3710586T1 (pl)
WO (1) WO2019092283A1 (pl)
ZA (1) ZA202003371B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009630C (en) 2015-12-16 2023-08-01 Amastan Technologies Llc Spheroidal dehydrogenated metals and metal alloy particles
US10987735B2 (en) 2015-12-16 2021-04-27 6K Inc. Spheroidal titanium metallic powders with custom microstructures
DK3607069T3 (da) * 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
HRP20230127T1 (hr) 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
KR20200109311A (ko) 2018-01-16 2020-09-22 다이서나 파마수이티컬, 인크. Aldh2 발현을 억제하기 위한 조성물 및 방법
CN112654444A (zh) 2018-06-19 2021-04-13 6K有限公司 由原材料制造球化粉末的方法
PH12021550801B1 (en) 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
BR112021019793A2 (pt) * 2019-04-04 2021-12-07 Dicerna Pharmaceuticals Inc Composições e métodos para inibir expressão de gene no sistema nervoso central
SG11202111576QA (en) 2019-04-30 2021-11-29 6K Inc Mechanically alloyed powder feedstock
CN114641462A (zh) 2019-11-18 2022-06-17 6K有限公司 用于球形粉末的独特原料及制造方法
MX2022007005A (es) * 2019-12-09 2022-08-25 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de lpa.
CA3180426A1 (en) 2020-06-25 2021-12-30 Richard K. Holman Microcomposite alloy structure
US12435336B2 (en) * 2020-08-05 2025-10-07 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting LPA expression
AU2021349358A1 (en) 2020-09-24 2023-02-09 6K Inc. Systems, devices, and methods for starting plasma
WO2022079221A1 (en) 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CA3196653A1 (en) 2020-10-30 2022-05-05 Sunil Bhalchandra BADWE Systems and methods for synthesis of spheroidized metal powders
AU2021373780A1 (en) * 2020-11-05 2023-06-08 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
AU2022206483A1 (en) 2021-01-11 2023-08-31 6K Inc. Methods and systems for reclamation of li-ion cathode materials using microwave plasma processing
WO2022212291A1 (en) 2021-03-31 2022-10-06 6K Inc. Systems and methods for additive manufacturing of metal nitride ceramics
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
KR20240103029A (ko) * 2021-11-18 2024-07-03 노파르티스 아게 샤르코 마리 투스 질환 치료용 pmp22 표적화 화합물
AU2022396536A1 (en) 2021-11-24 2024-06-06 Adarx Pharmaceuticals, Inc. Complement factor b-modulating compositions and methods of use thereof
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2023229928A1 (en) 2022-05-23 2023-11-30 6K Inc. Microwave plasma apparatus and methods for processing materials using an interior liner
US12040162B2 (en) 2022-06-09 2024-07-16 6K Inc. Plasma apparatus and methods for processing feed material utilizing an upstream swirl module and composite gas flows
JP2025522880A (ja) 2022-06-30 2025-07-17 アルナイラム ファーマシューティカルズ, インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2024044498A1 (en) 2022-08-25 2024-02-29 6K Inc. Plasma apparatus and methods for processing feed material utilizing a powder ingress preventor (pip)
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12195338B2 (en) 2022-12-15 2025-01-14 6K Inc. Systems, methods, and device for pyrolysis of methane in a microwave plasma for hydrogen and structured carbon powder production
WO2024151937A1 (en) * 2023-01-13 2024-07-18 Eli Lilly And Company Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
EP4709855A2 (en) 2023-05-12 2026-03-18 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
TW202509024A (zh) 2023-05-19 2025-03-01 大陸商深圳信立泰藥業股份有限公司 一種磺醯胺類化合物及其製備方法和醫藥用途
KR20260034652A (ko) 2023-07-04 2026-03-13 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 LP(a) 유전자 발현을 억제하기 위한 dsRNA 분자 및 그 용도
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA,含其的組合物及其用途
WO2025119212A1 (zh) * 2023-12-05 2025-06-12 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
WO2026008063A1 (en) * 2024-07-05 2026-01-08 Geneditbio Limited Methods and compositions for lpa gene editing and therapy using crispr system
WO2026046153A1 (zh) * 2024-08-26 2026-03-05 倍臻生物技术(苏州)有限公司 修饰的双链核糖核酸及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
WO2009151644A2 (en) * 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 rna 간섭을 유도하는 핵산 분자 및 그 용도
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
DK3607069T3 (da) 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
HRP20230127T1 (hr) 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
EP3735461A1 (en) 2017-11-13 2020-11-11 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of aldh2 in a cell
PH12021550801B1 (en) 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell

Also Published As

Publication number Publication date
EP3710586B1 (en) 2022-11-23
SI3710586T1 (sl) 2023-03-31
IL274503B1 (en) 2024-06-01
US20210123048A1 (en) 2021-04-29
US12054717B2 (en) 2024-08-06
JP7245254B2 (ja) 2023-03-23
IL274503A (en) 2020-06-30
MX2020004897A (es) 2020-10-05
US20240327843A1 (en) 2024-10-03
US20220290144A1 (en) 2022-09-15
BR112020009152A2 (pt) 2020-10-27
US11319537B2 (en) 2022-05-03
IL274503B2 (en) 2024-10-01
ES2938193T3 (es) 2023-04-05
EP3710586A1 (en) 2020-09-23
ZA202003371B (en) 2023-08-30
EP4219716A3 (en) 2024-03-27
HUE061265T2 (hu) 2023-06-28
AU2018363840B2 (en) 2022-09-29
AU2018363840A1 (en) 2020-04-16
HRP20230127T1 (hr) 2023-03-31
KR20200088392A (ko) 2020-07-22
WO2019092283A1 (en) 2019-05-16
EP4219716A2 (en) 2023-08-02
FI3710586T3 (fi) 2023-03-02
LT3710586T (lt) 2023-02-27
JP2021502120A (ja) 2021-01-28
SG11202003230UA (en) 2020-05-28
CA3081905A1 (en) 2019-05-16
DK3710586T3 (da) 2023-01-23
CN111465694A (zh) 2020-07-28
CN119120476A (zh) 2024-12-13
KR102553382B1 (ko) 2023-07-07
RS63955B1 (sr) 2023-02-28
CA3081905C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
IL274503A (en) Nucleic acids to inhibit LPA expression in the cell
SG11202103882QA (en) Nucleic acids for inhibiting expression of lpa in a cell
IL300438B1 (en) Compositions and methods for inhibiting lipoprotein A gene expression
ZA201700142B (en) Antisense nucleic acids
SG11201706636PA (en) Single-cell nucleic acids for high-throughput studies
ZA201605864B (en) Antisense nucleic acids
IL258065B (en) Nucleic acids against the coding strand
SG11201703493SA (en) Cell culture insert
GB201611982D0 (en) Cell culture
EP3351615A4 (en) CELL CULTURE VESSEL
PL3455339T3 (pl) Worek mający strukturę do hodowli komórkowej
EP3315596A4 (en) CELL CULTURE CONTAINER
PT3710586T (pt) Ácidos nucleicos para inibir a expressão de lpa numa célula
PL3365107T3 (pl) Hodowla komórek
IL290750A (en) Nucleic acids to inhibit expression of c3 in the cell
PL3287521T3 (pl) Hodowla komórkowa
HK40039639A (en) Nucleic acids for inhibiting expression of aldh2 in a cell
IL262067A (en) Biomass genes
SG10202010002RA (en) Cell culture